A global pharmaceutical company headquartered in Europe with offices worldwide is specialized in rare diseases, respiratory conditions, and critical care. The firm actively seeks partnerships with early-stage companies and is open to a variety of collaboration structures, including co-development, SAFE agreements, in-licensing, and acquisitions, depending on the opportunity.
Its Center for Open Innovation focuses on early-stage, pre-clinical assets, technologies, and digital or device-based healthcare solutions beyond the concept stage. Meanwhile, the business development and external innovation team engages with later-stage companies. With a strong international presence, the firm actively pursues opportunities across North America, Europe, and Asia.
The firm concentrates on rare diseases, respiratory health, and critical care. While its main focus is on therapeutics, it also considers diagnostics, medical devices, and digital health opportunities. The Center for Open Innovation targets assets in the target identification and optimization phases (TRL 3–5/6), prioritizing technologies that are novel and transformative rather than incremental.
Although the firm maintains defined therapeutic priorities, it remains open to adjacent or complementary innovation areas outside its existing pipeline.
The firm values partners that emphasize environmental sustainability and social responsibility. Ideal management teams bring complementary expertise and a clear commitment to delivering
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment